Tuesday, August 30, 2022
Revision Skincare®, a leading professional skincare brand, has announced a partnership with RVL Pharmaceuticals, Inc., the owner of UPNEEQ®, the first FDA-approved prescription eye drop for the treatment of acquired ptosis in adults.
This strategic collaboration brings together two disruptive companies in the aesthetics and skincare industries, both dedicated to providing high-quality results to patients. With shared values and a vision for business growth, the partnership aims to offer more accessible solutions to aesthetic patients and providers across the nation.
Revision Skincare® has been a pioneer in physician-dispensed brands for over two decades. Known for their use of peptides, proprietary technologies, and ingredient research, they develop clinically validated products that protect, treat, and enhance the skin.
RVL Pharmaceuticals, as a company focused on patient health, offers a nonsurgical solution for acquired ptosis with UPNEEQ®, which delivers results in as fast as 5 minutes.
"We are excited to partner with RVL Pharmaceuticals and join forces to offer breakthrough patient solutions," said Maria Carell, CEO, and President of Revision Skincare®.
Through this partnership, Revision Skincare® and RVL Pharmaceuticals will provide broader access to innovative products such as D·E·J Eye Cream®, Revox™ Line Relaxer, and UPNEEQ®. The companies plan to collaborate on various marketing efforts in the medical aesthetics industry, working together to address significant unmet consumer needs.
"We are thrilled to partner with Revision Skincare®! Their history of innovation and commitment to skin health aligns with our focus on ocular medical aesthetics," said Brian Markison, CEO of RVL Pharmaceuticals.
Revision Skincare® and RVL Pharmaceuticals share a dedication to innovation as they strive to meet the medical aesthetic needs of consumers, patients, and healthcare partners. For more information, individuals can contact their local aesthetic skincare professional's office.
